When Pfizer acquired Global Blood Therapeutics in October 2022, the flagship drug in the company’s portfolio was Oxbryta, a groundbreaking treatment that targets the root cause of sickle cell ...

Andrew Fein, an analyst from H.C. Wainwright, reiterated the Hold rating on Fulcrum Therapeutics (FULC – Research Report). The associated ...

Pfizer is voluntarily withdrawing its sickle cell disease (SCD) therapy Oxbryta from all world markets after finding an "imbalance" in deaths in its clinical trials programme. It's a blow to the ...

Pfizer's ex-chair and chief executive Ian Read ... GBT acquisition after the main asset in that $5.4 billion deal – Oxbryta for sickle cell disease – was pulled from the market last month.

Pfizer Inc. discovers, develops ... and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under ...

About Pfizer Inc. and Eli Lilly and Company Pfizer Inc. discovers ... and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable ...

The social campaign aimed to defy stigma, give voice to patients and care providers and pave the way for the launch of a ...

Pfizer, a multinational pharmaceutical and biotechnology corporation, is now a $159 billion (by market cap) healthcare giant. With business and stock excess seemingly totally wrung out, and with ...

Meenakshi Nevatia, Managing Director of Pfizer Limited on Tuesday said that the company is planning to expand its manufacturing capacity and it is focusing on research and development. Nevatia ...

Neurogene shares fell to $46. Pfizer sees promise of using wearables in drug trials When Pfizer earlier this year announced positive results of its treatment for the muscle-wasting condition ...

Pre-earnings options volume in Sonos (SONO) is 6.0x normal with calls leading puts 2:1. Implied volatility suggests the market is anticipating ...